Vasodilator Properties and Clinical Applications of Sodium Nitroprusside and Nitroglycerin

Comparison of Vasodilator Properties

Sodium nitroprusside is a balanced preload-reducing venodilator and afterload-reducing arteriodilator that also dilates the pulmonary vasculature 1
Nitroglycerin acts primarily through venodilation, lowering preload, and may help to rapidly reduce pulmonary congestion 2
Sodium nitroprusside has the potential for producing more marked hypotension than nitroglycerin, indicating its greater potency 1, 3

Sodium nitroprusside is potentially of value in severely congested patients with hypertension or severe mitral valve regurgitation complicating LV dysfunction 1
In acute cardiogenic pulmonary edema, nitroprusside is considered the drug of choice as it acutely lowers both ventricular preload and afterload 4
Intravenous nitroglycerin may develop tachyphylaxis within 24 hours, and up to 20% of those with heart failure may develop resistance to even high doses 1

For acute aortic disease, sodium nitroprusside can be used as an ultra-short acting vasodilating agent to immediately reduce blood pressure 5
In acute coronary events, sodium nitroprusside decreases regional blood flow in patients with coronary abnormalities, making nitroglycerin preferable in this specific situation 4

Due to its potency, sodium nitroprusside typically requires invasive hemodynamic blood pressure monitoring (such as an arterial line) 1
Blood pressure and volume status should be monitored frequently when using sodium nitroprusside 1
Longer infusions of sodium nitroprusside have been associated with thiocyanate toxicity, particularly in patients with renal insufficiency 1
Because of its potency and potential for toxicity, sodium nitroprusside is usually used in the intensive care setting 1

Tachyphylaxis to nitroglycerin may develop within 24 hours of continuous use 2, 1

The European Society of Cardiology recommends intravenous nitroglycerin as the preferred initial vasodilator for managing heart failure, particularly in the early phase of acute heart failure 6, 7, 8

The European Heart Society recommends nitroglycerin as first-line therapy in the early phase of acute heart failure 6, 7, 8
Initial recommended dose is 10-20 μg/min, increased in increments of 5-10 μg/min every 3-5 minutes as needed 6, 7
Nitroglycerin can be administered as spray, sublingual, or buccal preparations before continuous infusion 6
Effectively relieves pulmonary congestion without compromising stroke volume or increasing myocardial oxygen demand 6, 7, 8

Initial infusion rate should be 0.3 μg/kg/min with careful titration up to 5 μg/kg/min 6, 7
Requires arterial line monitoring due to its potency and risk of abrupt hypotension 6
Should be used cautiously in patients with acute coronary syndromes due to risk of abrupt hypotension 6, 7, 8

Tachyphylaxis commonly develops after 24-48 hours of nitroglycerin use, requiring incremental dosing 6, 7, 8
Headache is a common side effect of nitroglycerin 6, 7, 8

Both agents should be avoided in patients with systolic blood pressure <90 mmHg 6, 7, 8
Use with caution in patients with systolic blood pressure between 90-110 mmHg 6, 7, 8
Slow titration and frequent blood pressure monitoring is essential with both agents 6, 7, 8
Hypotension should be avoided, especially in patients with renal dysfunction 6, 7, 8
Marked hypotension may occur in patients with aortic stenosis following initiation of either vasodilator 6, 7, 8